Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy - achieving global consensus and visibility for cellular host-directed therapies

As of May 11th 2020, the coronavirus disease 2019 (COVID-19) pandemic, caused by the novel, the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has caused 274,361 deaths out of 3,917,366 (7% case fatality rate). As with the two other novel coronavirus zoonotic diseases of humans, SARS and MERS, no specific treatments for reducing mortality or morbidity are yet available. Deaths from COVID-19 will continue to rise globally until effective and appropriate treatments and vaccines are found.

Source: International Journal of Infectious Diseases - May 16, 2020 Category: Infectious Diseases Authors: Alimuddin Zumla, Fu-Sheng Wang, Giuseppe Ippolito, Nicola Petrosillo, Chiara Agrati, Esam I Azhar, Sherif A El-Kafrawy, Mohamed Osman, Laurence Zitvogel, Franco Locatelli, Ellen Gorman, Cecilia O'Kane, Danny Mcauley, Markus Maeurer Tags: Editorial Source Type: research